Nicholas Hollmeyer Lynton Sells 12,460 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLXGet Free Report) insider Nicholas Hollmeyer Lynton sold 12,460 shares of the company’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $13.69, for a total transaction of $170,577.40. Following the completion of the transaction, the insider now owns 71,355 shares of the company’s stock, valued at approximately $976,849.95. The sale was disclosed in a filing with the SEC, which is available at this link.

Nicholas Hollmeyer Lynton also recently made the following trade(s):

  • On Wednesday, January 3rd, Nicholas Hollmeyer Lynton sold 15,620 shares of Cardlytics stock. The shares were sold at an average price of $7.77, for a total transaction of $121,367.40.

Cardlytics Stock Down 2.5 %

Shares of Cardlytics stock opened at $13.31 on Thursday. The company has a market cap of $587.10 million, a P/E ratio of -3.85 and a beta of 1.44. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.31 and a current ratio of 1.31. Cardlytics, Inc. has a one year low of $4.33 and a one year high of $20.52. The firm has a fifty day moving average of $9.33 and a two-hundred day moving average of $9.82.

Analyst Ratings Changes

Several analysts recently commented on CDLX shares. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “buy” rating and upped their price target for the company from $10.00 to $18.00 in a research report on Friday, March 15th. Needham & Company LLC upped their price target on shares of Cardlytics from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Finally, Lake Street Capital upped their price target on shares of Cardlytics from $13.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, March 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $13.20.

Check Out Our Latest Analysis on Cardlytics

Hedge Funds Weigh In On Cardlytics

A number of large investors have recently bought and sold shares of CDLX. Invesco Ltd. raised its position in Cardlytics by 538.1% during the 3rd quarter. Invesco Ltd. now owns 803,241 shares of the company’s stock worth $13,253,000 after buying an additional 677,354 shares during the last quarter. Norges Bank purchased a new position in Cardlytics during the 4th quarter worth $2,338,000. Two Sigma Advisers LP raised its position in Cardlytics by 664.7% during the 3rd quarter. Two Sigma Advisers LP now owns 459,600 shares of the company’s stock worth $4,320,000 after buying an additional 399,500 shares during the last quarter. Baillie Gifford & Co. raised its position in Cardlytics by 30.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,436,220 shares of the company’s stock worth $8,301,000 after buying an additional 337,252 shares during the last quarter. Finally, UBS Group AG raised its position in Cardlytics by 210.5% during the 4th quarter. UBS Group AG now owns 174,822 shares of the company’s stock worth $1,010,000 after buying an additional 332,961 shares during the last quarter. Hedge funds and other institutional investors own 68.10% of the company’s stock.

Cardlytics Company Profile

(Get Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

See Also

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.